Arca
Skip to content
Tools
Tools

Warning Letter to Cellebration LLC

Biologics. See Cellebration's company page or this site's inspections.

On Sep 12, 2025, FDA's CBER sent Cellebration LLC a warning letter; it is not closed out.

  • Letter date: Sep 12, 2025
  • Issued by: CBER
  • Closeout: None yet

The Letter

As posted on FDA.gov โ†—; cited 21 CFR sections link to their page.

WARNING LETTER

September 12, 2025

CBER 25-713252

Dear Mr. Kaltner:

The United States Food and Drug Administration (FDA) reviewed your companyโ€™s website, https://www.cellebration.com/conditions (last visited September 2025), through which your company offers cellular products derived from cord blood for use in the treatment or prevention of various diseases or conditions, such as autism, cerebral palsy, chronic pain, colitis, Crohnโ€™s disease, degenerative disease, gout, liver cirrhosis, multiple sclerosis, neurological disorders, Parkinsonโ€™s disease, spine and disc conditions, sports injuries, and arthritis. As a result, your products are drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. ยง 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. ยง 262(i).

It is a prohibited act under section 301(e) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. ยง 331(e), to refuse to permit access to or copying of any record as required by section 704(a) of the FD&C Act, 21 U.S.C. ยง 374(a).

Under section 704(a)(4) of the FD&C Act, 21 U.S.C. ยง 374(a)(4), you are required to provide within a reasonable timeframe, within reasonable limits, and in a reasonable manner, requested records or information that FDA may inspect under section 704. However, your firm failed to comply with this requirement.

Specifically, on October 18, 2024, FDA sent an electronic request for records and other information pursuant to section 704(a)(4) of the FD&C Act to the above address. On November 5, 2024, you requested a 30-day extension to the submission deadline. You noted the additional time would allow your firm to โ€œwork closely with legal counsel to meet all standards and respond comprehensively.โ€ On November 13, 2024, FDA approved your extension request. On January 3, 2025, your firm requested a second 30-day extension due to the holidays and an unexpected illness. FDA approved this request on January 10, 2025. As you failed to answer our initial request for records, we sent a second request via e-mail on April 23, 2025. You indicated on April 28, 2025, that you had sent your response weeks earlier; however, our records reflect that no such response was received. On May 19, 2025, FDA requested that you resend the response referenced in your email. In response, you stated that you were unclear about what we were seeking. On May 21 and May 28, 2025, we sent additional follow-up emails again asking you to provide the requested records.

FDA has not received a response to its request to date even though FDAโ€™s request and follow-up communications sufficiently and clearly described the records sought. Your refusal to permit access to or copying of any record required by section 704(a), 21 U.S.C. ยง 374(a), violates section 301(e) of the FD&C Act, 21 U.S.C. ยง 331(e).

In response to this letter, we again ask you to provide the information and records requested by FDA pertaining to Cellebration, located at (b)(6) San Juan, PR, 00909, and your cellular products derived from cord blood.

Your firm should take prompt action to address this matter. This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action being initiated by FDA without further notice, including, without limitation, seizure and/or injunction.

We request that you respond in writing within fifteen (15) working days from your receipt of this letter. If you cannot address this matter within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.

Send your electronic response and any questions regarding this letter to CBERDCMRecommendations@fda.hhs.gov.

Sincerely, /S/

Melissa J. Mendoza Director Office of Compliance and Biologics Quality Center for Biologics Evaluation and Research

Cc:

George Kaltner Cellebration Regeneration Limited Liability Company 15 Ave. Munoz Rivera, Suite 103 Paseo Caribe, San Juan, PR 00901

Record

Recipient
George Kaltner
FDA site ID (FEI)
3032641083
Cited
โ€”

Tags are assigned by Arca from the letter's text. A closeout letter means FDA found the firm's corrections adequate; no closeout does not mean the issues are unresolved. FDA warning letters

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.